Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News PMV Pharmaceuticals Inc PMVP

Healthcare Biotechnology
PMV Pharmaceuticals, Inc. is a precision oncology company, which is engaged in discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53 is a tumor suppressor protein known as the guardian of the genome, and normal, or wild type, p53 has the ability to eliminate cancer cells. It is leveraging its precision oncology platform to develop a pipeline of orally... see more

Recent & Breaking News (NDAQ:PMVP)

PMV Pharmaceuticals Reports Third Quarter 2024 Financial Results

GlobeNewswire November 7, 2024

PMV Pharmaceuticals Provides a Progress Update on PYNNACLE Clinical Trial

GlobeNewswire October 23, 2024

PMV Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Progress Update on PYNNACLE Clinical Trial

GlobeNewswire August 8, 2024

PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in June

GlobeNewswire May 30, 2024

Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator

GlobeNewswire May 29, 2024

PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights

GlobeNewswire May 9, 2024

PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors

GlobeNewswire March 27, 2024

PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women's Cancer

GlobeNewswire March 18, 2024

PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights

GlobeNewswire February 29, 2024

PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care Conference

GlobeNewswire February 26, 2024

PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway

GlobeNewswire January 18, 2024

PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development

GlobeNewswire January 5, 2024

PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights

GlobeNewswire November 9, 2023

PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C Mutation

GlobeNewswire October 12, 2023

PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Host a KOL Webinar

GlobeNewswire October 11, 2023

PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

GlobeNewswire September 20, 2023

PMV Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Highlights

GlobeNewswire August 9, 2023

PMV Pharmaceuticals to Participate in the Goldman Sachs Global Healthcare Conference

GlobeNewswire June 6, 2023

PMV Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Highlights

GlobeNewswire May 10, 2023

PMV Pharmaceuticals Reports Full Year 2022 Financial Results and Corporate Highlights

GlobeNewswire March 1, 2023